The uncomfortable question lingers. In those nine years, how many died prematurely or endured avoidable disease progression because subsidised access was not available? If ministerial intervention was critical to this outcome, why did the system require it again?
The nine-year wait should raise some important but uncomfortable questions - can we be better?
March 1, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Just in case they didn't get the message, Mark Butler has reminded them of the Government's view
July 7, 2026 - - Latest News -
Australian Healthcare Associates retains deal to administer the CSO funding pool through 2029
July 7, 2026 - - Latest News -
Just another attempt to create a new excuse to avoid a meaningful discussion about change
July 7, 2026 - - Latest News -
Australia must keep development manufacturing and jobs here to secure health and economic benefits
July 7, 2026 - - Latest News -
Brandon Capital secures landmark Novartis acquisition of Myricx Bio
July 6, 2026 - - Latest News -
Vitex opens $250 million pharmaceutical manufacturing facility in Western Sydney
July 6, 2026 - - Latest News -
Early clinical imaging shows Syntara candidate reduces brain inflammation in people at high risk of Parkinson’s
July 6, 2026 - - Australian Biotech

